Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04462770
Other study ID # EPX-100-001
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 15, 2020
Est. completion date December 19, 2024

Study information

Verified date January 2024
Source Epygenix
Contact Lorianne Masuoka, M.D.
Phone (415) 933-0826
Email lm@epygenix.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of EPX-100 as adjunctive therapy in children and adult participants with Dravet Syndrome.


Description:

This is a global, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of EPX-100 as adjunctive therapy in children and adult participants with Dravet Syndrome. The study consists of a 4-week observational period, a 16-week double blind period and a 3-year open label extension.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 19, 2024
Est. primary completion date December 19, 2024
Accepts healthy volunteers No
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria: 1. Male and female participants 2 years and older at time of consent. 2. Participant or parent/Legally Authorized Representative (LAR) willing and able to provide written informed consent, assent (if applicable) prior to initiation of any study related procedures. 3. Clinical diagnosis of Dravet Syndrome. Participants must have seizures which are not completely controlled by AEDs with the following criteria: - Onset of seizures prior to 18 months of age, - Normal development at onset, - History of seizures that are generalized, unilateral clonic, and/or hemiclonic, - Brain MRI without cortical malformation (not including mild atrophy associated with the natural progression of Dravet Syndrome), and - Genetic mutation of the SCN1A gene must be documented. 4. The participant must be approved to participate by the Independent Reviewer, in collaboration with the PI. Participants will be approved for participation following review of the participant's medical and seizure history, historical neuroimaging, historical EEGs, genetic report confirming SCN1A mutation, and review and classification of at least 28 days of baseline seizures. 5. =4 countable convulsive seizures within minimum 28-day screening/baseline period (e.g., hemiclonic, secondarily generalized tonic-clonic, generalized tonic-clonic, tonic, clonic, tonic/atonic (resulting in a drop), and focal with clear observable motor signs). 6. Participants should be on a stable regimen of AEDs =30 days prior to Visit 1 and generally in good health. 7. Participant or parent/ LAR is able and willing to maintain an accurate and complete daily seizure and medication diary for the duration of the trial. 8. Sexually active women of child-bearing potential (WCBP) must be using a medically acceptable method of birth control and have a negative serum or urine pregnancy test at the screening (Visit 1) and Randomization (Visit 2). A WCBP is defined as a female who is biologically capable of becoming pregnant. A medically acceptable method of birth control includes intrauterine devices in place for at least 3 months, surgical sterilization, or adequate barrier methods (e.g., diaphragm and foam). Use of oral contraceptives in combination with another method (e.g., a spermicidal cream) is acceptable. In participants who are not sexually active, abstinence is an acceptable form of birth control and urine will be tested per protocol. Women who are of non-child-bearing potential, i.e., post-menopause, must have this condition captured in their medical history. Pregnant women are excluded from this study. Exclusion Criteria: The presence of any of the following excludes a participant from study enrollment: 1. Known sensitivity, allergy, or previous exposure to EPX-100 (clemizole HCl). 2. Exposure to any investigational drug or device <90 days prior to screening or plans to participate in another drug or device trial at any time during the study. 3. Seizures secondary to illicit drug or alcohol use, infection, neoplasm, demyelinating disease, degenerative neurological disease, or central nervous system (CNS) disease deemed progressive, metabolic illness, or progressive degenerative disease. 4. Concurrent use of drugs known to interfere with EPX-100, including moderate or severe inducers or inhibitors of CYP3A4/5/7. Specifically, concurrent use of carbamazepine, oxcarbazepine and/or phenytoin, as well as refraining from grapefruits and grapefruit juice during the study period. Refer to Appendix 1 for a list of prohibited drugs. 5. Prior or concurrent use of lorcaserin. 6. Concurrent use of fenfluramine. Participants with prior use of fenfluramine within the previous 3 months, or without proper documentation of an echocardiogram, at minimum 3 months following the last dose of fenfluramine, to ensure that the participant does not meet any criteria for drug-related (fenfluramine) cardiac valvular heart disease and/or drug-related pulmonary arterial hypertension (PAH) as indicated by any of the following: - documented mild or greater aortic regurgitation [AR] or moderate or greater mitral regurgitation [MR] - significant (greater than mild) tricuspid regurgitation - abnormally thickened cardiac valve and/or has restricted motion of the valve leaflets - elevated right heart/pulmonary artery pressure >35mmHg 7. Has any medical condition that, in the PI's judgment, is considered to be clinically significant and could potentially affect participant safety or study outcome, including but not limited to: clinically significant cardiac disease (including angina, congestive heart failure, uncontrolled hypertension, and history of arrhythmias), renal, pulmonary, gastrointestinal, hematologic or hepatic conditions; or a condition that affects the absorption, distribution, metabolism, or excretion of drugs. 8. Has an active suicidal plan/intent or have had active suicidal thoughts in the past 6 months or a suicide attempt in the past 3 years.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
EPX-100 (Clemizole HCl)
Daily dose of EPX100
Placebo
Daily dose of Placebo

Locations

Country Name City State
Canada Children's Hospital of Eastern Ontario Ottawa Ontario
Canada The Hospital for Sick Children Toronto Ontario
Canada Toronto Western Hospital, University Health Network Toronto Ontario
Canada UBC Children's Hospital Research Institute Vancouver British Columbia
Georgia LEPL Tbilisi State Medical University, Givi Zhvania Academic, Clinic of Pediatry Tbilisi
Georgia LTD Institute of Neurology and Neuropsychology Tbilisi
Georgia LTD Medi Club Georgia LLC Tbilisi
Hungary Semmelweis University First Department of Pediatrics, Division of Child Neurology Budapest
Spain Hospital de la Santa Creu i Sant Pau Barcelona Catalonia
Spain Hospital Universitario Infantil Niño Jesús Madrid Madrid Provincia
United States University of Michigan- Mott Children's Hospital Ann Arbor Michigan
United States Child Neurology Consultants of Austin Austin Texas
United States Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois
United States Cincinnati Children's Hospital Cincinnati Ohio
United States Cleveland Clinic Cleveland Ohio
United States Nationwide Children's Hospital Columbus Ohio
United States Northeast Regional Epilepsy Group Hackensack New Jersey
United States Children's Hospital of Los Angeles Los Angeles California
United States Le Bonheur Children's Hospital Memphis Tennessee
United States Weill Cornell Medicine/New York-Presbyterian Hospital New York New York
United States Children's Hospital & Medical Center Omaha Nebraska
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States University of Utah Salt Lake City Utah
United States UCSF Medical Center San Francisco California
United States Seattle Children's Seattle Washington
United States Nemours Children's Hospital-DE Wilmington Delaware
United States Wake Forest Baptist Health Sciences Department of Neurology Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Epygenix

Countries where clinical trial is conducted

United States,  Canada,  Georgia,  Hungary,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary The mean percent change in countable convulsive seizure frequency (CCSF1) in the Titration and Maintenance (T+M) periods relative to baseline. The mean percent change in countable convulsive seizure frequency (CCSF1) in the Titration and Maintenance (T+M) periods relative to baseline. 20 weeks
Secondary The difference between EPX-100 vs placebo in the number of countable convulsive seizure-free days in the T+M periods relative to baseline. The difference between EPX-100 vs placebo in the number of countable convulsive seizure-free days in the T+M periods relative to baseline. 20 weeks
Secondary The difference between EPX-100 vs placebo in proportion of participants with >50% reduction in the mean CCSF in the T+M periods relative to baseline. The difference between EPX-100 vs placebo in proportion of participants with >50% reduction in the mean CCSF in the T+M periods relative to baseline. 20 weeks
Secondary The total change in Seizure Severity using Hague Seizure Severity Scale (HASS). The total change in Seizure Severity using Hague Seizure Severity Scale (HASS). 20 weeks
Secondary The improvement in Clinical Global Impression (CGI). The improvement in Clinical Global Impression (CGI). 20 weeks
Secondary The total change in Quality of Life in Childhood Epilepsy short form (QOLCE 55). The total change in Quality of Life in Childhood Epilepsy short form (QOLCE 55). 20 weeks
Secondary The difference between EPX-100 vs placebo in proportion of participants with >25% reduction in the mean CCSF in the T+M periods relative to baseline. The difference between EPX-100 vs placebo in proportion of participants with >25% reduction in the mean CCSF in the T+M periods relative to baseline. 20 weeks
Secondary The mean difference between EPX-100 vs placebo per 28-days in the percent change of all seizures in the T+M periods relative to the baseline. The mean difference between EPX-100 vs placebo per 28-days in the percent change of all seizures in the T+M periods relative to the baseline. 20 weeks
Secondary The change in the number of episodes of status epilepticus, in the T+M periods relative to the baseline. The change in the number of episodes of status epilepticus, in the T+M periods relative to the baseline. 20 weeks
Secondary The incidence of rescue anti-epileptic drug (AED) use between EPX-100 and placebo, as measured by the number of days on rescue AEDs in the T+M periods relative to the baseline. The incidence of rescue anti-epileptic drug (AED) use between EPX-100 and placebo, as measured by the number of days on rescue AEDs in the T+M periods relative to the baseline. 20 weeks
Secondary The individual item changes in Quality of Life in Childhood Epilepsy short form (QOLCE 55). The individual item changes in Quality of Life in Childhood Epilepsy short form (QOLCE 55). 20 weeks
Secondary The individual item changes in Seizure Severity using Hague Seizure Severity Scale (HASS). The individual item changes in Seizure Severity using Hague Seizure Severity Scale (HASS). 20 weeks
Secondary The change in the Sleep Disturbance Scale for Children (SDSC) between EPX-100 and placebo by each scheduled visit The change in the Sleep Disturbance Scale for Children (SDSC) between EPX-100 and placebo by each scheduled visit 20 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05651204 - GABA Biomarkers in Dravet Syndrome
Withdrawn NCT02910297 - The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy
Completed NCT02896608 - Neuronal Excitability of HCN1 Channel Mutations in Dravet Syndrome
Withdrawn NCT05140122 - LEONIDaS Caregivers Study
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT02091206 - A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1) Phase 2
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT05472389 - Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome N/A
Active, not recruiting NCT05626634 - Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Phase 2
Recruiting NCT01858285 - Genetics of Epilepsy and Related Disorders
Recruiting NCT04614506 - Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome
Recruiting NCT06118255 - A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome Phase 3
Recruiting NCT04611438 - Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome Phase 3
Completed NCT02091375 - Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1) Phase 3
Completed NCT05364021 - Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies Phase 1/Phase 2
Recruiting NCT06112275 - A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only) Phase 1/Phase 2
Withdrawn NCT03254680 - Turmeric as Treatment in Epilepsy N/A
Terminated NCT02187809 - Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome Phase 3
Withdrawn NCT02174094 - Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome Phase 3
Completed NCT02823145 - An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome Phase 3